Replimuneβs mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patientβs lives depend on it. We imagine a world where cancer is a curable disease.Β
β―At Replimune, we live by our values:Β
United: We Collaborate for a Common Goal.Β
Audacious: We Are Bold and Innovative.Β
Dedicated: We Give Our Full Commitment.Β
Candid: We Are Honest With Each Other.Β
People are at the center of everything we do, and when it comes to our employees, we make it personal.β― With a deep sense of purpose, an innovative and collaborative culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity toβ―contribute to the meaningful work we do which could impact the lives of patients.Β Β
β―Join us, as we reshape the future.Β
Β
Job Summary:Β
As the Strategic Account Manager (SAM) at Replimune, you'll take center stage as the key liaison for our valued customers, equipping them with the latest clinical insights on our products. Your role involves effectively conveying the clinical advantages and reimbursement landscape of our offerings to healthcare professionals including physicians, pharmacists, advanced practice providers and other relevant stakeholders involved with patient care.Β
Β
Β This is a field based position.β― Candidates must reside within the territory for which they are applying.Β
Β
Β
Education:β―β―Β
β―Β
Required Experience:Β
β―Β
Aboutβ―Replimuneβ―Β
Replimune Group, Inc., headquartered inβ―Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimuneβs proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visitβ―www.replimune.com.Β
β―Β
We are an Equal Opportunity Employer.Β
#LI-Remote